EGLT - Egalet Corporation

NasdaqGM - NasdaqGM Delayed Price. Currency in USD

Egalet Corporation

600 Lee Road
Suite 100
Wayne, PA 19087
United States
610-833-4200
http://www.egalet.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees154

Key Executives

NameTitlePayExercisedAge
Mr. Robert S. RadieChief Exec. Officer, Pres and Director798.77kN/A54
Dr. Mark Strobeck Ph.D.Chief Operating Officer and Exec. VP531.77kN/A46
Mr. Patrick M. SheaChief Commercial Officer137.9kN/A52
Mr. Stanley J. Musial CPA, MBAChief Financial Officer, Exec. VP and Sec.N/AN/A56
Ms. Barbara A. CarlinChief Accounting OfficerN/AN/A42
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Egalet Corporation, a specialty pharmaceutical company, develops, manufactures, and commercializes treatments for patients with pain and other conditions. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic moderate to severe pain where an opioid is appropriate; and ARYMO ER, an extended-release (ER) morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The company is also developing Egalet-002, a Guardian Technology AD, ER, oral oxycodone formulation, which is in Phase III clinical trials for the same indication as ARYMO ER. In addition, its other products include Egalet-003, an AD stimulant product candidate; and Egalet-004, an AD, ER hydrocodone-based product candidate. The company has a collaboration and license agreement with Acura Pharmaceuticals, Inc. to commercialize OXAYDO tablets; and Septodont, Inc. to promote SPRIX Nasal Spray. Egalet Corporation was founded in 2010 and is headquartered in Wayne, Pennsylvania.

Corporate Governance

Egalet Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.